Sage is representing EpiAxis Therapeutics. We are seeking strategic partners to license their novel technology for epigenetic control of metastatic cancer.
EpiAxis Therapeutics is a leading epigenetics company targeting the nuclear bound lysine-specific demethylase 1 (LSD1) enzyme. The company discovered the dual role that LSD1 plays in reprograming the epigenome in metastatic disease and has novel, best in class inhibitors, against this pivotal target.
EpiAxis’ inhibitors reverse both the epithelial to mesenchymal transition (EMT) of the metastasis initiating cells and, in parallel, redecorate the phenotype of immune T cells to restore and reinvigorate their function in metastatic disease.
Research identifying this target and the IP that resulted from these discoveries was developed at The University of Canberra (UC) by Professor Sudha Rao and colleagues.
EpiAxis’ peptidomimetic inhibitors are dual-acting and non-catalytic in action. They target both a novel nuclear pocket, responsible for the nuclear entry of LSD1 and in parallel, disrupt the LSD1/ CoRest complex. Phenelzine sulfate is being used clinically in a first of its kind Phase 1B program to validate this target.
The initial disease indication is metastatic breast cancer. Other solid tissue tumors, such as ovarian, pancreatic, colon, melanoma, lung and liver cancers are of secondary focus.
EpiAxis is positioning itself to become the leading metastasis prevention company, with the aim of having its proprietary LSD1 inhibitors as Standard of Care (SoC) therapies.
Please contact us at The Sage Group in Europe or USA:
Dr. Bill Mason
+44 7785 950134
+1 908 2306170